Search Results
Results found for "Zack Zurawski"
- Chemical Drug Matter : Rethinking the Molecules We Choose to Develop In Drug Discovery
stall not because the target is wrong—but because the chemical matter interacting with that target lacks
- The Five Traps of Ignoring Kinetics
And once you see it, you’ll never go back.
- Curve Shifts Don’t Lie, But Your Eyes Might
And once you make that shift, you’ll never go back.
- Understanding the Journey: Catherine Demery's Path to Addiction Science
It was mostly just because, I need to be back in the lab.”
- Unveiling GPCR Priming: The Hidden Synergy in Cellular Signalling
Using CRISPR-Cas9 knockout HEK cells lacking Gs proteins, a study by Stallaert et al. in 2017 showed
- 📰 GPCR Weekly News, May 1 to 7, 2023
Jack Antel to its clinical advisory board Crinetics Pharmaceuticals First Quarter 2023 Earnings: Revenues
- 📰 GPCR Weekly News, July 17 to July 23, 2023
Premium members can always go back and watch the recorded talks at any time.
- The Hidden Driver of GPCR Drug Success: Why Target Residence Time Matters More Than You Think
With over 21,000 views and 7,785 downloads from Volume I, the Signal Transduction Research Topic is back
- 📰 GPCR Weekly News, June 5 to 11, 2023
Our website is updated as we confirm speakers so please check back often.
- 📰 GPCR Weekly News, February 13 to 19, 2023
From outside to inside and back again: the lysophosphatidic acid-CCN axis in signal transduction.
- Beyond Clearance: The Strategic Power of Irreversible Drug Binding
This is where seasoned drug hunters separate themselves from the pack—not just knowing the kinetics ,
- 📰 GPCR Weekly News, September 18 to 24, 2023
If you couldn't make it, no sweat – our premium members can always go back and watch the recorded talks
- 📰 GPCR Weekly News, August 28 to September 3, 2023
pathophysiology and treatment of CNS disorders GPCRs in Oncology and Immunology From outside to inside and back
- 📰 GPCR Weekly News, February 26 to March 3, 2024
a resounding success; we have a waitlist for those eager to attend this course, which wil be coming back
- How Understanding Intracellular Drug Access Can Transform Your GPCR Drug Discovery Program
Welcome back GPCR fans, The pace of GPCR innovation is accelerating at a rate that can be difficult to
- How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology
a cold email from a biologist he’d never met, asking if he could synthesize a molecule “when you’re back
- 📰 Breaking Down the Latest GPCR Discoveries: a Weekly Update (Nov 27-Dec 3, 2023)
Deep Learning Dynamic Allostery of G-Protein-Coupled Receptors Industry News Sosei Heptares to take back
- 🤯Mind-blowing GPCR Scoops! Discover the Latest Breakthroughs! ⦿ Nov 18 - 24, 2024
platform to connect from anywhere in the world And if you go for a Premium Membership , you'll not only back
- 📰 GPCR Weekly News, November 20 to 26, 2023
with Multispan Cell Engineering and Assay Services $3bn sales potential for drug Sosei Heptares wants back
- Harnessing Deep Mutational Scanning for Enhanced Drug Discovery
Additionally, DMS is not universally applicable to all proteins; it struggles with proteins that lack
- Competitive vs Non-Competitive GPCR Antagonists: How to Interpret Pharmacology Data with Confidence
Welcome back GPCR lovers, In pharmacology, the wrong interpretation of antagonist behavior can derail
- Why Biotech Fundraising Fails Due to Intellectual Property Gaps
It is the lack of alignment between intellectual property and business intent. 2️⃣ Ownership and control
- Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls
Unexpected outcomes typically trace back to a single issue: transferring assumptions from idealized models
- The Hidden Burn: How Internal Misalignment Drains Your Biotech’s Runway
This breeds passive execution, second-guessing, and a lack of ownership .
- From Failed Experiments to Predictive GPCR Models
His lab has already begun using AlphaFold models to identify ligands for targets that lack experimental
- ⛵Sailing the GPCR Seas: Your Weekly Research Voyage! ⦿ Nov 11 - 17, 2024
with AEF0217 in young adults with Down syndrome Novartis pays Schrödinger $150M, bets billions on the back
- Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery
In every lab, candidates fail not because they lack potency at a receptor, but because they stumble at
- Structural landscape of the Chemokine Receptor system
CKRs can be classified into typical CKRs, atypical CKRs (ACKRs) which lack G-protein signaling, and viral variants of CCL15, namely CCL15L (residues 26-92) and CCL15M (residues 27-92), while the third structure lacks
- The Moment Biotech Founders Realize the Money Is Gone
. 👉 The issue is not a lack of intelligence or discipline.
- How Early Strategic Decision Making Creates Alignment and Better Results
👉 Most founders look back at the end of the year and try to make sense of the results.



















